Xiangzheng Fu
Overview
Explore the profile of Xiangzheng Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Z, Wei J, Liu M, Zhuo L, Fu X, Zou Q
BMC Biol
. 2025 Mar;
23(1):73.
PMID: 40069807
Background: Single-cell RNA sequencing (scRNA-seq) is now essential for cellular-level gene expression studies and deciphering complex gene regulatory mechanisms. Deep learning methods, when combined with scRNA-seq technology, transform gene regulation...
2.
Xu J, Lu C, Jin S, Meng Y, Fu X, Zeng X, et al.
Nucleic Acids Res
. 2025 Mar;
53(5).
PMID: 40037709
Gene regulatory networks (GRNs) provide a global representation of how genetic/genomic information is transferred in living systems and are a key component in understanding genome regulation. Single-cell multiome data provide...
3.
Zhang X, Wang H, Du Z, Zhuo L, Fu X, Cao D, et al.
IEEE J Biomed Health Inform
. 2025 Mar;
29(3):1759-1770.
PMID: 40030556
Investigating the inhibitory effects of compounds on cardiac ion channels is essential for assessing cardiac drug safety. Consequently, researchers have developed computational models to evaluate combined cardiotoxicity (CCT) on cardiac...
4.
Peng L, Li H, Yuan S, Meng T, Chen Y, Fu X, et al.
J Chem Inf Model
. 2025 Feb;
65(4):2129-2144.
PMID: 39937612
In the emerging field of RNA drugs, circular RNA (circRNA) has attracted much attention as a novel multifunctional therapeutic target. Delving deeper into the intricate interactions between circRNA and disease...
5.
Cai L, Yue G, Chen Y, Wang L, Yao X, Zou Q, et al.
Brief Bioinform
. 2025 Jan;
26(1.
PMID: 39783892
Motivation: Accurately predicting the degradation capabilities of proteolysis-targeting chimeras (PROTACs) for given target proteins and E3 ligases is important for PROTAC design. The distinctive ternary structure of PROTACs presents a...
6.
Wei J, Wang L, Zhou Z, Zhuo L, Zeng X, Fu X, et al.
IEEE J Biomed Health Inform
. 2024 Nov;
PP.
PMID: 39527419
Cloud computing and Internet of Things (IoT) technologies are gradually becoming the technological changemakers in cancer diagnosis. Blood cancer is an aggressive disease affecting the blood, bone marrow, and lymphatic...
7.
Wei J, Zhuo L, Fu X, Zeng X, Wang L, Zou Q, et al.
BMC Biol
. 2024 Oct;
22(1):226.
PMID: 39379930
Drug repurposing is a promising approach in the field of drug discovery owing to its efficiency and cost-effectiveness. Most current drug repurposing models rely on specific datasets for training, which...
8.
Yu S, Liu L, Wang H, Yan S, Zheng S, Ning J, et al.
Methods
. 2024 Sep;
231:61-69.
PMID: 39293728
Arabidopsis thaliana synthesizes various medicinal compounds, and serves as a model plant for medicinal plant research. Single-cell transcriptomics technologies are essential for understanding the developmental trajectory of plant roots, facilitating...
9.
Wang T, Zhuo L, Chen Y, Fu X, Zeng X, Zou Q
PLoS Comput Biol
. 2024 Aug;
20(8):e1012400.
PMID: 39213450
The identification of cancer driver genes (CDGs) poses challenges due to the intricate interdependencies among genes and the influence of measurement errors and noise. We propose a novel energy-constrained diffusion...
10.
Wei X, Zhu T, Yip H, Fu X, Jiang D, Deng Y, et al.
Chem Sci
. 2024 Aug;
PMID: 39170720
The identification of targets for candidate molecules is a pivotal stride in the drug development journey, encompassing lead discovery, drug repurposing, and the scrutiny of potential off-target or side effects....